Perspective Therapeutics Inc (CATX)

Perspective Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing precision targeted alpha therapies for cancer treatment in the United States. Its pipeline includes VMT-a-NET, which is being studied in Phase 1/2a trials for patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors who have not previously received peptide-targeted radiopharmaceutical therapy; VMT01, which is in Phase 1/2a testing for second-line or later treatment of progressive MC1R-positive metastatic melanoma; PSV359, a targeted alpha therapy directed at fibroblast activation protein alpha; and PSV4XX, a PSMA-targeted alpha therapy. The company also has a clinical collaboration with Bristol Myers Squibb to assess [212Pb] VMT01 together with nivolumab in patients with melanoma and positive MC1R imaging scans. Founded in 2004 and headquartered in Seattle, Washington, the company was previously known as Isoray, Inc. before adopting its current name in 2022.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.